MOLECULIN BIOTECH, INC. (MBRX)
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
📈 **POSITIVE** • Medium confidence analysis (76%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical